



Codul proiectului/Project's code: PN-III-P1-1.1-TE-2021-0366

Titlul proiectului/Project's title: „Terapie țintită pentru tratamentul melanomului bazată pe co-administrarea de anticorpi specifici față de PD-L1 și vezicule extracelulare cu curcumină”/ “Targeted therapy for the treatment of melanoma based on co-administration of anti-PD-L1 antibodies and curcumin-loaded extracellular vesicles”

Denumirea poziției vacante/ Name of the vacant post: Asistent de cercetare științifică/ Research Assistant (PhD student)

Bibliografie/Bibliography

1. Patras, L., & Banciu, M. (2019). Intercellular Crosstalk Via Extracellular Vesicles in Tumor Milieu as Emerging Therapies for Cancer Progression. *Current pharmaceutical design*, 25(17), 1980–2006. <https://doi.org/10.2174/1381612825666190701143845>
2. Patras, L., Fens, M., Vader, P., Barendrecht, A., Sesarman, A., Banciu, M., & Schiffelers, R. (2020). Normoxic Tumour Extracellular Vesicles Modulate the Response of Hypoxic Cancer and Stromal Cells to Doxorubicin In Vitro. *International journal of molecular sciences*, 21(17), 5951. <https://doi.org/10.3390/ijms21175951>
3. Rauca, V. F., Licarete, E., Luput, L., Sesarman, A., Patras, L., Bulzu, P., Rakosy-Tican, E., & Banciu, M. (2018). Combination therapy of simvastatin and 5, 6-dimethylxanthenone-4-acetic acid synergistically suppresses the aggressiveness of B16.F10 melanoma cells. *PloS one*, 13(8), e0202827. <https://doi.org/10.1371/journal.pone.0202827>
4. Negrea, G., Rauca, V. F., Meszaros, M. S., Patras, L., Luput, L., Licarete, E., Toma, V. A., Porfire, A., Muntean, D., Sesarman, A., & Banciu, M. (2022). Active Tumor-Targeting Nano-formulations Containing Simvastatin and Doxorubicin Inhibit Melanoma Growth and Angiogenesis. *Frontiers in pharmacology*, 13, 870347. <https://doi.org/10.3389/fphar.2022.870347>
5. Patras, L., Ionescu, A. E., Munteanu, C., Hajdu, R., Kosa, A., Porfire, A., Licarete, E., Rauca, V. F., Sesarman, A., Luput, L., Bulzu, P., Chiroi, P., Tranca, R. A., Meszaros, M. S., Negrea, G., Barbu-Tudoran, L., Potara, M., Szedlacsek, S., & Banciu, M. (2022). Trojan horse treatment based on PEG-coated extracellular vesicles to deliver doxorubicin to melanoma *in vitro* and *in vivo*. *Cancer biology & therapy*, 23(1), 1–16. <https://doi.org/10.1080/15384047.2021.2003656>
6. Fontana F, Marzagalli M, Sommariva M, Gagliano N, Limonta P. In Vitro 3D Cultures to Model the Tumor Microenvironment. *Cancers (Basel)*. 2021 Jun 13;13(12):2970. doi: 10.3390/cancers13122970. PMID: 34199324; PMCID: PMC8231786.
7. Boucherit, N., Gorvel, L., & Olive, D. (2020). 3D Tumor Models and Their Use for the Testing of Immunotherapies. *Frontiers in immunology*, 11, 603640. <https://doi.org/10.3389/fimmu.2020.603640>
8. Sun, D., Zhuang, X., Xiang, X., Liu, Y., Zhang, S., Liu, C., Barnes, S., Grizzle, W., Miller, D., & Zhang, H. G. (2010). A novel nanoparticle drug delivery system: the anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes. *Molecular therapy : the journal of the American Society of Gene Therapy*, 18(9), 1606–1614. <https://doi.org/10.1038/mt.2010.105>
9. Liu, J., Chen, Z., Li, Y., Zhao, W., Wu, J., & Zhang, Z. (2021). PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy. *Frontiers in pharmacology*, 12, 731798. <https://doi.org/10.3389/fphar.2021.731798>
10. Curran, M. A., Montalvo, W., Yagita, H., & Allison, J. P. (2010). PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. *Proceedings of the National Academy of Sciences of the United States of America*, 107(9), 4275–4280. <https://doi.org/10.1073/pnas.0915174107>

11. Lai, C., Duan, S., Ye, F., Hou, X., Li, X., Zhao, J., Yu, X., Hu, Z., Tang, Z., Mo, F., Yang, X., & Lu, X. (2018). The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide. *Theranostics*, 8(6), 1723–1739. <https://doi.org/10.7150/thno.22056>